Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction

Journal of Cardiology

Volumn 44, Issue 2, 2004, Pages 47-52

  Hirahara, Taishi ^a   Kubo, Norifumi ^a   Ohmura, Nobuhiro ^a   Matsushima, Kazuo ^a   Fujii, Mikihisa ^a   Yasu, Takanori ^a   Ikeda, Nahoko ^a   Saito, Muneyasu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Complications; Coronary intervention; Myocardial infarction, treatment; Restenosis; Thrombin inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; TICLOPIDINE; WARFARIN; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CORONARY STENT; EVALUATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZATION; RESTENOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY RESTENOSIS; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; PIPECOLIC ACIDS; PROSPECTIVE STUDIES;

EID: 4544327364     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Yasu T, Oshima S, Imanishi M, Nonogi H, Haze K, Kuramochi M, Omae T, Hayashi Y, Yamamoto S: Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol 1993; 71: 1164-1168
2. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
3. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990; 67: 1552-1561
4. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
5. Tabata H, Mizuno K, Miyamoto A, Etsuda H, Nagayoshi H, Hakamada N, Satomura K, Shibuya T, Arakawa H, Kurita A, Nakamura N: Prevention of reocclusion by argatroban, selective thrombin inhibitor, following recanarization therapy in patients with acute myocardial infarction: Comparative effects of argatroban and heparin. Jpn J Med Pharm Sci 1993; 29: 107-110 (in Japanese)
6. Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83: 1510-1518
7. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP Jr: A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA)in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33: 1879-1885
8. Herrman JP, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW: Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J Thromb Thrombolysis 1996; 3: 367-375
9. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, for the TAMI Study Group: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791
10. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA: Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-291
11. Rutherford BD, Hartzler GO, Moconahay DR, Johnson WL Jr: Direct balloon angioplasty in acute myocardial infarction: Without prior use of streptokinase. J Am Coll Cardiol 1986; 7(Suppl): 149A(abstr)
12. Rapold HJ, Bono DD, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M, for the European Cooperative Study Group: Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85: 928-934
13. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC: Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243
14. Sakurada M, Kikuchi T, Miyake T: Prevention of reocclusion after PTCA by antithrombotic agent. Pharma Medicine 1999; 17: 87-91 (inJapanese)
15. The EPIC investigators: Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
16. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ, for the ReoPre and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators: Randomized, placebo-controlled trial of platelet glycoprotein II b/III a blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-741